The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Genmab; Merck Serono; MSD; Regeneron; Seagen
Speakers' Bureau - AstraZeneca; Eisai; MSD; Roche; Takeda
Research Funding - Abbvie (Inst); Advenchen Laboratories (Inst); Alkermes (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); BMS (Inst); CanariaBio (Inst); Cellid (Inst); CKD pharm (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); genemedicine (Inst); Genmab (Inst); GI Innovation (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Janssen Oncology (Inst); Kelun (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); onconic therapeutics (Inst); Ono Pharmaceutical (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Sutro Biopharma (Inst); Synthon (Inst); Takeda (Inst); Torl Biotherapeutics (Inst); Zymeworks (Inst)
Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians’ choice in advanced/recurrent endometrial carcinoma previously treated with anti–PD-(L)1 immunotherapy.
 
Ramez Eskander
Consulting or Advisory Role - AbbVie; AstraZeneca/MedImmune; BioNTech SE; Daiichi Sankyo/Lilly; Eisai; Gilead Sciences; GlaxoSmithKline; Immunogen; Merck; Myriad Genetics; Pfizer; PMV Pharma; Regeneron; Seagen
Research Funding - Acrivon Therapeutics (Inst); AstraZeneca (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nivectis (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Merck
Other Relationship - GOG Foundation
 
Jung-Yun Lee
No Relationships to Disclose
 
Mansoor Mirza
Stock and Other Ownership Interests - Karyopharm Therapeutics; Sera Prognostics
Honoraria - Allarity Therapeutics; AstraZeneca; Biocad; BioNTech; Boehringer Ingelheim; Clovis Oncology; Daiichi Sankyo; DualityBio; Eisai; Genmab; GlaxoSmithKline; ImmunoGen; Incyte; Karyopharm Therapeutics; Merck; Mersana; Novartis; Nykode Therapeutics; Regeneron; Roche; SeaGen; Takeda; Tesaro; Zai Lab
Research Funding - Allarity Therapeutics; Apexigen; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; GlaxoSmithKline; Novartis; Tesaro; Ultimovacs
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo/Lilly; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Novocure; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; ImmunoGen; MSD; Seagen
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Pharma& (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Menarini
(OPTIONAL) Uncompensated Relationships - ENGOT; Gynecological Cancer InterGroup; MITO
 
Helen Mackay
Honoraria - AstraZeneca; GlaxoSmithKline
Consulting or Advisory Role - Eisai; GlaxoSmithKline; Merck
 
Isabelle Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; IMMUNOCORE; Immunogen; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; PMV Pharma; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Corcept Therapeutics; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Immunocore; Immunogen; Incyte; Macrogenics; Mersana; MSD Oncology; Netris Pharma; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Scorpion Therapeutics; seagen; Seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES
 
Ana Oaknin
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Debiopharm Group; Deciphera; Eisai; Exelixis; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Myriad Genetics; Novocure; OncoXerna Therapeutics; PharmaMar; Regeneron; Roche; Seagen / Pfizer; Shattuck Labs; Sutro Biopharma; TORL Therapuetics; Zentalis; Zymeworks
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Immunogen; MSD; Roche
Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Antonio Gonzalez Martin
Consulting or Advisory Role - Abbvie; Alkermes; Amgen; AstraZeneca; BioNTech SE; Clovis Oncology; Daiichi Sankyo; Eisai; Genmab; Hedera Dx; Immunogen; Incyte; Kartos Therapeutics; Macrogenics; Mersana; MSD; Novartis; Novocure; Oncoinvent; Pfizer/EMD Serono; Pharma&; Regeneron; Roche; Seagen; SOTIO; Sutro Biopharma; Takeda; Tesaro/GSK; Torl Biotherapeutics; Tubulis GmbH
Speakers' Bureau - AstraZeneca; Clovis Oncology; MSD Oncology; PHARMA&; PharmaMar; Roche; Tesaro/GSK
Research Funding - Roche (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Genmab; Kyowa Kirin; MSD K.K; Regeneron; Sanofi; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Genmab; Kaken Pharmaceutical; Merck KGaA; MSD K.K; Regeneron; Roche; Sanofi; Takeda; Zymeworks
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical
 
Bradley Corr
Consulting or Advisory Role - AstraZeneca/Merck (Inst); Corcept Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunogen; Imvax; Merck (Inst); Zentalis (Inst)
Research Funding - Clovis Oncology (Inst); Immunogen (Inst)
 
Xiaohua Wu
No Relationships to Disclose
 
Alexandra Leary
Honoraria - Gerson Lehrman Group; Medscape; peervoice
Consulting or Advisory Role - Abbvie (Inst); Apmonia Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Merck Serono (Inst); MSD (Inst); PEGASCY; Pharmend (Inst); Seagen (Inst); Tesaro (Inst); zentalis (Inst)
Research Funding - Adaptimmune (Inst); AstraZeneca (Inst); Inivata (Inst); MSD Oncology (Inst); OSE Immunotherapeutics (Inst); owkin (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Oseimmuno; Tesaro
 
Tianle Hu
Employment - Kura Oncology
 
Lea Dutta
Employment - Eisai
 
Chinyere Okpara
Employment - Eisai
 
Jodi McKenzie
Employment - Eisai
 
Vicky Makker
Consulting or Advisory Role - ArQule; Clovis Oncology; DualityBio; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; ITeos Therapeutics; Kartos Therapeutics; Karyopharm Therapeutics; Lilly; Merck; Novartis; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); DualityBio (Inst); Eisai (Inst); Faeth Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai; ESMO Congress; Merck
Other Relationship - IBM